Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECIST: Autologous DC Therapy in Pancreatic Adenocarcinoma
NCT04157127Phase 1Recruiting
- Sponsor
- Diakonos Oncology
- Start
- Aug 2020
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial in pancreatic adenocarcinoma (PDAC) and pancreatic adenosquamous carcinoma (PASC) (3 arms), sponsored by Diakonos Oncology. Primary endpoints: Safety of DC Therapy at 6 weeks and Dose Limiting Toxicities at 6 weeks. Started Aug 2020; status: recruiting.
02
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on NCT04157127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157127.